Top Tech Startups in Asia in 2026

clyzo.com An established player in the B2B Pharma raw material space has recently launched an exciting new E-commerce platform – CLYZO We are one of the leading distributor in India especially for Excipients. Our principals is from Europe who have put their faith and trust in our abilities to establish and consolidate their brands in India. Our client are all reputed Pharma companies whom we are serving since last 14 years. We maintain around 200 Pharma grade products in ready inventory for JIT supply. We have launched the next generation, first of its kind B2B e-commerce platform focused on Pharma Raw Materials. We are now looking for a seasoned marketing professional to head the marketing department. This individual will be an integral part of the core team and will be responsible for multi-functional marketing activities.

Unified HCM Platform for Learning Management, Training, Compensation, and Performance Management

Maroon is a hybrid cryptocurrency exchange that combines a centralised order book with hybrid deposit wallets for which the user always retains a key. Through a smooth UX that enables and encouraging self-custody, we turn the “Don’t be evil” ethos into a “Can’t be evil” reality.

ASPL Fusion (Agnira Sanlayan Pvt. Ltd.) is building India's first commercial neutron technology platform. Starting with BNCT cancer therapy and medical isotope production, our technology trajectory leads to clean fusion energy. Our platform addresses three massive markets: 1. Cancer Therapy (BNCT): Building India's first Boron Neutron Capture Therapy centre — a targeted radiation treatment that kills tumour cells while sparing healthy tissue. 30+ million cancer patients could benefit globally. 2. Medical Isotopes: India imports 100% of its diagnostic and therapeutic isotopes. We are building domestic production capability for Tc-99m, Lu-177, Cu-64, and 7 other critical isotopes using our Gas-Dynamic Trap fusion device. 3. Clean Energy: Our fusion technology trajectory, built on revenue-generating medical applications, leads to commercial fusion power by 2038-2040. Founded by Prof. Prabhat Ranjan (former Director, Institute for Plasma Research — India's national fusion lab) and a team of nuclear scientists and engineers. Key facts: - DPIIT startup recognition: DIPP222699 - Pragmatic four-phase development strategy generating revenue from Rung 0 - World-class advisory board including Prof. Y.C. Saxena (former Head, FCIPT/IPR) - Deep partnerships with IPR, BARC, and IREL for technology and regulatory access - Accelerator-based neutron source (2.5 MeV proton beam on Li-7 target) - Proprietary simulation IP validated against IPR experimental neutron data We are not waiting for fusion to work before generating revenue. Our near-term medical applications (BNCT, isotopes) fund the long-term fusion mission. This is the pragmatic path to fusion energy.

We work hands-on with ventures from early validation through scale-up, providing shared infrastructure, operational excellence, and execution discipline — while keeping ventures autonomous and founder-led. Our model is decentralized and pragmatic: - flat hierarchies - strong ownership - decisions grounded in data The venture builder exists to accelerate execution, not to centralize power or slow teams down.